[1] |
Wicklund MP, Kissel JT. The limb-girdle muscular dystrophies. Neurol Clin, 2014, 32(3): 729-749.
doi: 10.1016/j.ncl.2014.04.005
pmid: 25037088
|
[2] |
Liewluck T, Milone M. Untangling the complexity of limb-girdle muscular dystrophies. Muscle Nerve, 2018, 58(2): 167-177.
doi: 10.1002/mus.26077
pmid: 29350766
|
[3] |
Chu M L, Ellen M. The limb-girdle muscular dystrophies: is treatment on the horizon? Neurotherapeutics, 2018, 15(4): 849-862.
doi: 10.1007/s13311-018-0648-x
pmid: 30019308
|
[4] |
Cirak S, Foley AR, Herrmann R, Willer T, Yau S, Stevens E, Torelli S, Brodd L, Kamynina A, Vondracek P, Roper H, Longman C, Korinthenberg R, Marrosu G, Nürnberg P, Consortium U, Michele DE, Plagnol V, Hurles M, Moore SA, Sewry CA, Campbell KP, Voit T, Muntoni F. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. Brain, 2013, 136(Pt 1): 269-281.
doi: 10.1093/brain/aws312
|
[5] |
Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord, 1995, 5(1): 71-74.
|
[6] |
Angelini C. LGMD. Identification, description and classification. Acta Myol, 2020, 39(4): 207-217.
doi: 10.36185/2532-1900-024
pmid: 33458576
|
[7] |
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med, 2015, 17(5): 405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
[8] |
Luo SS, Lu JH. Limb-girdle muscular dystrophy. Chin J Neurol, 2019, 52(7): 573-581.
|
|
罗苏珊, 卢家红. 肢带型肌营养不良. 中华神经科杂志, 2019, 52(7): 573-581.
|
[9] |
Muntoni F, Brockington M, Blake DJ, Torelli S, Brown SC. Defective glycosylation in muscular dystrophy. Lancet, 2002, 360(9343): 1419-1421.
pmid: 12424008
|
[10] |
Waite A, Brown SC, Blake DJ. The dystrophin- glycoprotein complex in brain development and disease. Trends Neurosci, 2012, 35(8): 487-496.
doi: 10.1016/j.tins.2012.04.004
|
[11] |
Yang H Y, Cai F, Liao H G, Gan S Y, Xiao T, Wu L W. Case report: ISPD gene mutation leads to dystroglycanopathies: genotype phenotype analysis and treatment exploration. Front Pediatr, 2021, 9: 710553.
|
[12] |
Turan S, Farruggio AP, Srifa W, Day JW, Calos MP. Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol Ther, 2016, 24(4): 685-696.
doi: 10.1038/mt.2016.40
pmid: 26916285
|
[13] |
Pedemonte N, Lukacs GL, Kai D, Caci E, Zegarra-Moran O, Galietta LJV, Verkman AS. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest, 2005, 115(9): 2564.
doi: 10.1172/JCI24898
|
[14] |
Carotti M, Marsolier J, Soardi M, Bianchini E, Gomiero C, Fecchio C, Henriques SF, Betto R, Roberta Sacchetto R, Richard L, Sandonà D. Repairing folding-defective a-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D. Hum Mol Genet, 2018, 27(6): 969-984.
doi: 10.1093/hmg/ddy013
|
[15] |
Riemersma M, Froese DS, van Tol W, Engelke UF, Kopec J, van Scherpenzeel M, Ashikov A, Krojer T, von Delft F, Tessari M, Buczkowska A, Swiezewska E, Jae LT, Brummelkamp TR, Manya H, Endo T, van Bokhoven H, Yue WW, Lefeber DJ. Human ISPD is a cytidyltransferase required for dystroglycan O-mannosylation. Chem Biol, 2015, 22(12): 1643-1652.
doi: 10.1016/j.chembiol.2015.10.014
|